CBLI - クリ―ブランド・バイオラブ (Cleveland BioLabs Inc.) クリ―ブランド・バイオラブ

 CBLIのチャート


 CBLIの企業情報

symbol CBLI
会社名 Cleveland BioLabs Inc (クリ―ブランド・バイオラブ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クリーブランド・バイオラブズ(Cleveland BioLabs Inc. )は臨床段階のバイオテクノロジー企業であり、腫瘍治療用医薬品の開発に取り組む。同社の主力薬品候補である「CBLB502」は、放射線対策として、一般的に動物ルール(Animal Rule)と呼ばれ、米国食品医薬品局(FDA)の動物有効性ルール(Animal Efficacy Rule)の下で、並びに抗がん剤と腫瘍支持療法としてFDAの従来の新薬承認経路下で、二重適応症のために開発されたものである。平成23年12月31日現在、同社の製品パイプラインにおける9つの薬品候補は同社自体およびその過半数所有子会社により直接的に開発されている。当該製品は「CBLB502」、「CBLB502」、「CBLB502」、「CBLB612」、「CBLC102」、「CBLC137、」「Revercom」、「Mobilan」、「Arkil」、「Antimycon」及び「Xenomycins」を含む。平成23年12月31日現在、同社はIncuron LLC (Incuron)の約75.8%の持分を所有し、Panacela Labs Inc. (Panacela)の約54.6%の持合株式を所有している。   クリ―ブランド・バイオラブは、米国の薬剤開発会社。医療ニ―ズが満たされていない病気に対処する医薬品の設計や開発に従事する。細胞死を制御するための薬理学的アプロ―チ、がん細胞を消滅させ、健康な細胞を保護することに焦点を当てる。 主要製品は、「Entolimod」と「CBL0137」がある。  
本社所在地 73 High Street Buffalo NY 14203 USA
代表者氏名 Langdon L. Miller Langdon L. Miller
代表者役職名 President 社長
電話番号 +1 716-849-6810
設立年月日 37773
市場名 NASDAQ Small Cap
ipoyear 2006年
従業員数 19人
url www.cbiolabs.com
nasdaq_url https://www.nasdaq.com/symbol/cbli
adr_tso
EBITDA EBITDA(百万ドル) -5.29598
終値(lastsale) 1.9799
時価総額(marketcap) 22369383.3961
時価総額 時価総額(百万ドル) 22.25753
売上高 売上高(百万ドル) 1.78640
企業価値(EV) 企業価値(EV)(百万ドル) 15.73004
当期純利益 当期純利益(百万ドル) -4.50562
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cleveland BioLabs Inc. revenues decreased 21% to $619K. Net loss decreased 71% to $2.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Change in value of warrant liability increase from $4.2M (expense) to $679K (income) Research and development decrease of 14% to $2.2M (expense).

 CBLIのテクニカル分析


 CBLIのニュース

   SHAREHOLDER ALERT: WeissLaw LLP Reminds TLRY, CBLI, AKER and OBLN Shareholders About Its Ongoing Investigations  2021/03/19 19:42:00 PR Newswire
NEW YORK, March 19, 2021 /PRNewswire/ -- Tilray, Inc. (NASDAQ: TLRY) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tilray, Inc. (NASDAQ: TLRY) in connection with the company's proposed merger with Aphria Inc….
   SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations  2021/03/12 20:31:00 Benzinga
NEW YORK , March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: CONTACT: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor New York , NY 10036 (212) 682-3025 (888) 593-4771 Full story available on Benzinga.com
   Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock - Stocks News Feed  2021/02/19 18:38:38 Stocks News Feed
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share in a registered direct offering. The closing… Read More »Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock
   Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock  2021/02/19 18:30:00 Yahoo Finance
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   SHAREHOLDER ALERT: WeissLaw LLP Reminds TLRY, CBLI, AKER and OBLN Shareholders About Its Ongoing Investigations  2021/03/19 19:42:00 PR Newswire
NEW YORK, March 19, 2021 /PRNewswire/ -- Tilray, Inc. (NASDAQ: TLRY) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tilray, Inc. (NASDAQ: TLRY) in connection with the company's proposed merger with Aphria Inc….
   SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations  2021/03/12 20:31:00 Benzinga
NEW YORK , March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: CONTACT: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor New York , NY 10036 (212) 682-3025 (888) 593-4771 Full story available on Benzinga.com
   Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock - Stocks News Feed  2021/02/19 18:38:38 Stocks News Feed
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share in a registered direct offering. The closing… Read More »Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock
   Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock  2021/02/19 18:30:00 Yahoo Finance
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock - Stocks News Feed  2021/02/19 18:38:38 Stocks News Feed
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share in a registered direct offering. The closing… Read More »Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock
   Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock  2021/02/19 18:30:00 Yahoo Finance
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   40 Stocks Moving in Thursday's Pre-Market Session  2021/02/18 12:28:36 Benzinga
Gainers Heritage Global Inc. (NASDAQ: HGBL ) shares rose 153.3% to $7.80 in pre-market trading. Heritage Global Partners, and a subsidiary of Heritage Global Inc. recently announced partnership with Cloud Investment Partners to conduct auction of MD-80 assets from iAero Thrust. U.S. Well Services, Inc. (NASDAQ: USWS ) shares rose 81.5% to $4.30 in pre-market trading. US Well Services, on Wednesday, received Nasdaq listing extension. HighCape Capital Acquisition Corp. (NASDAQ: CAPA ) rose 54% to $15.98 in pre-market trading. Quantum-Si announced plans to combine with HighCape Capital Acquisition Corp. Cleveland BioLabs, Inc. (NASDAQ: CBLI ) rose 53.3% to $13.00 in pre-market trading. Cleveland BioLabs filed registration statement on Form S-4 in connection with previously announced proposed merger with Cytocom Inc. Avinger, Inc. (NASDAQ: AVGR ) rose 40.8% to $2.38 in pre-market trading as traders circulated US Patent & Trademark Office February 10, 2021-dated application for the company’s 'Optical Pressure Sensor Assembly.' Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) rose 37.3% to $6.22 in pre-market trading.
   Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.  2021/02/17 21:15:00 PR Newswire
FORT COLLINS, Colo. and BUFFALO, N.Y., Feb. 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a registration statement on Form S-4 (the "Registration Statement") with…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クリ―ブランド・バイオラブ CBLI Cleveland BioLabs Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)